U.S. Patent Litigations
PACER
Case No(s):
U.S. Patent Nos.
8,563,698 (Antigen Binding Proteins to Proprotein Convertase Subtilisin Kexin Type 9 (PCSK9)) 8,829,165 (Antigen Binding Proteins to Proprotein Convertase Subtilisin Kexin Type 9 (PCSK9)) 8,859,741 (Antigen Binding Proteins to Proprotein Convertase Subtilisin Kexin Type 9 (PCSK9)) 8,871,913 (Antigen Binding Proteins to Proprotein Convertase Subtilisin Kexin Type 9 (PCSK9)) 8,871,914 (Antigen Binding Proteins to Proprotein Convertase Subtilisin Kexin Type 9 (PCSK9)) 8,883,983 (Antigen Binding Proteins to Proprotein Convertase Subtilisin Kexin Type 9 (PCSK9)) 8,889,834 (Antigen Binding Proteins to Proprotein Convertase Subtilisin Kexin Type 9 (PCSK9))
Plaintiffs
Amgen Inc.; Amgen Manufacturing, Ltd.; Amgen USA, Inc.
Defendants
Regeneron Pharmaceuticals, Inc.; Sanofi; Sanofi-Aventis US LLC; Aventisub LLC
Federal Circuit Appeal(s)
17-1480
Supreme Court Appeal(s)
18-127
Status
District Court Determination that Patents Valid and Infringed; Federal Circuit Decision Reversing-In-Part, Affirming-In-Part, Vacating-In-Part, and Remanding for New Trial on Written Description and Enablement; Remand Pending; Petition for Rehearing En Banc Denied; Supreme Court Writ of Certiorari Denied
BPCIA
N
U.S. Patent Nos.
8,871,913 (Antigen Binding Proteins to Proprotein Convertase Subtilisin Kexin Type 9 (PCSK9)) 8,871,914 (Antigen Binding Proteins to Proprotein Convertase Subtilisin Kexin Type 9 (PCSK9))
Plaintiffs
Amgen Inc.
Defendants
Regeneron Pharmaceuticals, Inc.; Sanofi; Sanofi-Aventis US LLC; Aventisub LLC
Federal Circuit Appeal(s)
17-1480
Supreme Court Appeal(s)
18-127
Status
Consolidated with 1:14-cv-01317 (D. Del.); Federal Circuit Decision Reversing-In-Part, Affirming-In-Part, Vacating-In-Part, and Remanding in Lead Case; Remand Pending (1:14-cv-01317; Fed. Cir. 2017-1480); Supreme Court Writ of Certiorari Denied
BPCIA
N
U.S. Patent Nos.
8,883,983 (Antigen Binding Proteins to Proprotein Convertase Subtilisin Kexin Type 9 (PCSK9))
Plaintiffs
Amgen Inc.
Defendants
Regeneron Pharmaceuticals, Inc.; Sanofi; Sanofi-Aventis US LLC; Aventisub LLC
Federal Circuit Appeal(s)
17-1480
Supreme Court Appeal(s)
18-127
Status
Consolidated with 1:14-cv-01317 (D. Del.); Federal Circuit Decision Reversing-In-Part, Affirming-In-Part, Vacating-In-Part, and Remanding in Lead Case; Remand Pending (1:14-cv-01317; Fed. Cir. 2017-1480); Supreme Court Writ of Certiorari Denied
BPCIA
N
U.S. Patent Nos.
8,889,834 (Antigen Binding Proteins to Proprotein Convertase Subtilisin Kexin Type 9 (PCSK9))
Plaintiffs
Amgen Inc.
Defendants
Regeneron Pharmaceuticals, Inc.; Sanofi; Sanofi-Aventis US LLC; Aventisub LLC
Federal Circuit Appeal(s)
17-1480
Supreme Court Appeal(s)
18-127
Status
Consolidated with 1:14-cv-01317 (D. Del.); Federal Circuit Decision Reversing-In-Part, Affirming-In-Part, Vacating-In-Part, and Remanding in Lead Case; Remand Pending (1:14-cv-01317; Fed. Cir. 2017-1480); Supreme Court Writ of Certiorari Denied
BPCIA
N
U.S. Patent Nos.
7,923,221 (Methods of Making Antibody Heavy and Light Chains having Specificity for a Desired Antigen)
Plaintiffs
Regeneron Pharmaceuticals, Inc.; Sanofi-Aventis US LLC
Defendants
City of Hope; Genentech, Inc.
Status
Dismissed
BPCIA
N